AURITEC PHARMACEUTICALS, LLC
- PASADENA, CA 91107-3658
- Corporate Entity (Not Tax Exempt)
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
- Small Business
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
AURITEC PHARMACEUTICALS, LLC has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About AURITEC PHARMACEUTICALS, LLC
- Headquarters
- PASADENA, CA 91107-3658
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIQX8KP6JKQ2L8
- CAGE414W4
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 30 awards
- Total awarded
- $25,454,161
- By phase
- SBIR Phase I: 15
- SBIR Phase II: 14
- STTR Phase I: 1
- By agency
- Department of Health and Human Services: 30
- Active projects
- 0 projects
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 0 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2023: 1
- 2022: 1
- 2021: 1
- 2020: 1
- 2019: 2
- 2018: 1
- 2017: 1
- 2016: 2
- 2015: 2
- 2013: 3
- 2012: 2
- 2011: 1
- 2010: 1
- 2009: 2
- 2007: 3
- 2006: 2
- 2005: 3
- 2004: 1
Awards (most recent first)
IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $3,050,000
Sep 14, 2023 – Aug 31, 2026
Solicitation PA22-176 (2022) · Topic NIAID
Long-acting injectable tacrolimus for chronic immunosuppression
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2022 · $2,047,614
Jul 8, 2022 – Jun 30, 2024
- Direct to Phase II
Solicitation PA21-259 (2021) · Topic NIAID
Longer-acting intravaginal formulation of buprenorphine
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2021 · $1,690,670
Sep 1, 2021 – Aug 31, 2023
Solicitation DA19-019 (2019) · Topic NIDA
I-Corps: Longer-acting intravaginal formulation of buprenorphine
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $308,608
Sep 30, 2020 – Aug 31, 2021
Solicitation PA19-029 (2019) · Topic NIDA
IND-enabling preclinical development of a system for the multipurpose prevention of HIV and unintended pregnancy
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $1,999,996
Jul 22, 2019 – Jun 30, 2021
Solicitation PA18-574 (2018) · Topic NIAID
IND-enabling preclinical development of a sustained-release Pritelivir intravaginal ring for the treatment and prophylaxis of Genital Herpes in women
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $1,860,561
Apr 4, 2019 – Mar 31, 2021
Solicitation PA18-574 (2018) · Topic NIAID
Preclinical development of an intravaginal ring for the sustained release of Pritelivir for the treatment and prophylaxis of Genital Herpes in women
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $224,484
Feb 1, 2018 – Apr 3, 2019
Solicitation PA16-302 (2016) · Topic NIAID
Preclinical development of an intravaginal ring for the sustained release of octreotide for the treatment of acromegaly
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $224,881
Sep 1, 2017 – Aug 31, 2019
Solicitation PA16-302 (2016) · Topic NICHD
Clinical Safety and Pharmacokinetics of Sustained Release Depot Tacrolimus
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2016 · $1,299,084
Aug 15, 2016 – Jul 31, 2019
Solicitation PAR13-250 (2013) · Topic NIAID
Preclinical development of a multipurpose intravaginal ring for the prevention of HIV and unintended pregnancy
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $219,324
Jul 8, 2016 – Jun 30, 2018
Solicitation PA15-269 (2015) · Topic R
Automation of GMP manufacturing of HIV microbicide rings
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2015 · $1,482,501
Sep 24, 2015 – Jun 30, 2018
Solicitation PA14-071 (2014) · Topic 105
Clinical safety and pharmacokinetic studies of intravaginal rings releasing multiple antiretrovirals
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2015 · $1,301,280
Apr 1, 2015 – Mar 31, 2018
Solicitation PA14-071 (2015) · Topic NICHD
An intravaginal ring for real-time evaluation of adherence to topical vagina
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2013 · $211,862
Solicitation PA12-089 (2013) · Topic NIAID · Research partner: OAK CREST INSTITUTE OF SCIENCE
A Flow Through Cell Counting Assay
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2013 · $338,981
Solicitation PA12-088 (2013) · Topic NICHD · Research partner: Stub
Depot intra-articular fluticasone for the treatment of arthritis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2013 · $1,191,901
Solicitation PA12-088 (2013) · Topic NIAMS · Research partner: Stub
Intravaginal ring delivery of tenofovir and emtricitabine
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $300,000
Solicitation PA11-096 (2012) · Topic NIAID · Research partner: Stub
Sustained Release intravitreal VEGFR inhibition to prevent blindness
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $296,405
Solicitation PA11-096 (2012) · Topic NEI · Research partner: Stub
Preclinical development of a tenofovir intravaginal ring for HIV prophylaxis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2011 · $2,993,089
Solicitation PA10-123 (2011) · Topic NIAID · Research partner: Stub
Sustained Release Depot Olanzapine
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2010 · $1,073,890
Solicitation PHS2010-2 (2010) · Topic NIMH
Sustained release acyclovir for prophylaxis of genital herpes
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2009 · $223,952
Solicitation PHS2009-2 (2009)
Depot calcineurin inhibitors to prevent graft rejection
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2009 · $1,330,820
Solicitation PHS2009-2 (2009)
Sustained release calcineurin inhibitors for the prevention of graft rejection
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2007 · $99,120
Solicitation year 2007
Sustained Release Inner Ear Delivery of Corticosteroid
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2007 · $99,550
Solicitation year 2007
Sustained Release Apomrophine for Parkinson's Disease
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2007 · $326,938
Solicitation year 2007
Sustained Release Intravitreal Corticosteroid Injections
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2006 · $99,368
Solicitation PHS2006-2 (2006)
Showing the 25 most recent of 30 awards.
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541714Research and Development in Biotechnology (except Nanobiotechnology)PrimarySmall business under this code’s size standard
SAM.gov reports this entity as small under 1 of 1 NAICS code. Size is determined per code (SBA size standards).
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with AURITEC PHARMACEUTICALS, LLC?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.